Hansa Biopharma — August 2023
-
Manglende insiderkøb hos ledelsen, giver stadig shorterne grobund for indtjening. Og det skaber desværre forvirring og usikkerhed hos mange aktionærer, at Tulstrup og den øvrige ledelse
ikke skaber positive signaler hos aktionærerne via insiderkøb på det nuværende kursniveau:-( -
Den ene af de "3 shortere", har tilsyneladende forladt Hansa Biopharma;-)https://insidevoice.se/bolag/hansa-medical
ja samme kurs udvikling som de sidste mange mange mdr. hvor vil det klæde ledelsen/bestyrelsen at selv begynde at købe op i casen det vil skabe ro og tro på fremtiden
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind